Abstract 348P
Background
Malignant melanoma is an extremely rare malignancy in the Indian subcontinent and South east Asia. Its already known that Asian countries have different clinical presentation of melanoma. It would be interesting to know the epidemiology and outcome of advanced disease in Indian patients.
Methods
We retrospectively analysed patients with malignant melanoma who were registered in Medical Oncology clinic at AIIMS, New Delhi between January 2016 and July 2019. We used SPSS version 23 for analysis. Immunotherapy used was single agent Nivolumab as Ipilimumab is unavailable.
Results
Total of 93 patients (57 males, 36 females) were registered in the study. Median age was 53 (range, 25 to 85 years), with the commonest primary sites being anorectal (n = 23) and foot (n = 23), followed by eye (n = 15), head and neck (n = 12), thigh (n = 9), others (n = 11) respectively. The commonest sites of metastasis were lymph nodes (n = 54, 58.1%), lung (n = 45,48.4%), liver(n = 33,35.5%) and bone(n = 25,26.9%).The median sites of metastasis was two (range 1-5). Most patients had ECOG PS 1-2 (n = 77, 82.8%). Majority of the patients (n = 80,86%) had metastasis.Out of 93 patients, 39(42%) received chemotherapy in first line, 16 (17.3%) received Immunotherapy, 13 (13.9%) underwent surgery and best supportive care was offered to 25 (26.8%) patients. The chemotherapy used were dacarbazine (n = 27), nabpaclitaxel (n = 6) and others (n = 6). Among patients who received chemo, median number of cycles was 5 (range,1-15) and response assessment revealed progressive disease in 17 patients, stable disease in 4 patients, partial response in one patient, and remaining 16 patients defaulted and were not evaluable. Among patients who received Single agent Nivolumab, the median number of cycles was 5 (range,2-15) and response showed progressive disease in all patients, except one. Median follow up was 18 months and median PFS was 3 months.
Conclusions
This study shows that the site of melanoma in Indian patients is different as compared to western patients with higher number of anorectal, mucosal and acral melanoma. Immunotherapy was feasible for only a fraction of patients in view of exorbitant cost. Non availability of BRAF therapies and Ipilimumab is of great concern in view of poor outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
220P - An outcome analysis of robotassisted radical nephroureterectomy with extended template lymphadenectomy for upper tract urothelial carcinoma
Presenter: Ashwin Tamhankar
Session: Poster display session
Resources:
Abstract
221P - Comparative analysis of first-line immune checkpoint inhibitor versus carboplatin-based chemotherapy for cisplatin-ineligible metastatic urothelial carcinoma: A multicenter, retrospective real-world evidence
Presenter: Hsiang‐Lan Lai
Session: Poster display session
Resources:
Abstract
222P - Does tumor grade really improve the prognostic ability of the staging system for men with penile cancer: A SEER database analysis
Presenter: Ravi Kanodia
Session: Poster display session
Resources:
Abstract
223TiP - EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma
Presenter: Daniel Petrylak
Session: Poster display session
Resources:
Abstract
230P - Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort
Presenter: Lingying Wu
Session: Poster display session
Resources:
Abstract
231P - Cost-effectiveness of olaparib vs routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
Presenter: David SP Tan
Session: Poster display session
Resources:
Abstract
233P - Incorporation of correlative studies in ovarian cancers in the era of precision medicine: Assessment of accountability and utility
Presenter: Nadia Hitchen
Session: Poster display session
Resources:
Abstract
234P - Implementation of mainstream BRCA testing in epithelial ovarian cancer in a tertiary centre
Presenter: Edbert Wong
Session: Poster display session
Resources:
Abstract
235P - The efficacy of radiation therapy in ovarian carcinoma: A propensity score analysis of a population-based study
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
236P - Front-line maintenance therapy for platinum-sensitive ovarian cancer: What’s next PARP inhibitors?
Presenter: Han Gong
Session: Poster display session
Resources:
Abstract